REGULATED PRESS RELEASE published on 04/12/2024 at 07:45, 5 months 7 days ago Successful capital increase for NFL Biosciences with over €3 million raised NFL Biosciences successfully raises over €3 million in capital increase, securing funds for upcoming Phase 3 clinical trial of NFL-101 and advancing development of NFL-301. New shares to be listed on Euronext Growth Paris on April 16, 2024 NFL Biosciences Capital Increase NFL-101 Phase 3 Clinical Trial NFL-301
REGULATED PRESS RELEASE published on 04/12/2024 at 07:45, 5 months 7 days ago Succès de l’opération de NFL Biosciences avec plus de 3 millions d’euros levés par voie d’augmentation de capital
BRIEF published on 04/11/2024 at 17:50, 5 months 8 days ago NFL Biosciences annonce une levée de fonds de 3 millions d'euros NFL Biosciences NFL-101 Levée De Fonds Phase 3 NFL-301
BRIEF published on 04/11/2024 at 17:50, 5 months 8 days ago NFL Biosciences Initiates €3 Million Fundraising Through Capital Increase NFL Biosciences Addiction Treatment Fundraising Clinical Trials Capital Increase
REGULATED PRESS RELEASE published on 04/11/2024 at 17:45, 5 months 8 days ago NFL Biosciences launches a fundraising round for 3 million euros through a capital increase NFL Biosciences launches a fundraising round for 3 million euros through a capital increase, aiming to support Phase 3 clinical trial for NFL-101 and development of NFL-301 drug candidates NFL Biosciences Capital Increase NFL-101 Phase 3 Clinical Trial Fundraising Round
REGULATED PRESS RELEASE published on 04/11/2024 at 17:45, 5 months 8 days ago NFL Biosciences lance une levée de fonds d’environ 3 millions d’euros par voie d’augmentations de capital NFL Biosciences lance une levée de fonds d'environ 3 millions d'euros pour financer ses candidats médicaments NFL-101 et NFL-301 en développement NFL Biosciences Candidats Médicaments NFL-101 Levée De Fonds NFL-301
REGULATED PRESS RELEASE published on 04/02/2024 at 08:00, 5 months 17 days ago NFL BIOSCIENCES SHOWCASES THE RESULTS OF ITS STUDIES TO THE SCIENTIFIC AND PHARMACEUTICAL COMMUNITIES
REGULATED PRESS RELEASE published on 04/02/2024 at 08:00, 5 months 17 days ago NFL BIOSCIENCES VALORISE SES RÉSULTATS D’ÉTUDES AUPRÈS DE LA COMMUNAUTÉ SCIENTIFIQUE ET PHARMACEUTIQUE
REGULATED PRESS RELEASE published on 03/29/2024 at 17:45, 5 months 21 days ago NFL BIOSCIENCES: 2023 FULL-YEAR BUSINESS AND EARNINGS UPDATE
REGULATED PRESS RELEASE published on 03/29/2024 at 17:45, 5 months 21 days ago NFL BIOSCIENCES : ACTIVITÉS & RÉSULTATS ANNUELS 2023
Published on 09/19/2024 at 23:15, 13 minutes ago Cypher Metaverse Inc. Announces Second Closing of Financing
Published on 09/19/2024 at 23:00, 28 minutes ago WestJet Partners with FLYHT and NOAA to Improve Weather Forecasting in North America
Published on 09/19/2024 at 20:15, 3 hours 13 minutes ago Living Security Named a Leader in Human Risk Management, Closely Watched Tech Industry Report
Published on 09/19/2024 at 21:09, 2 hours 19 minutes ago EQS-Adhoc: Mercedes-Benz Group AG adjusts full-year guidance for the year 2024 based on current market outlook
Published on 09/19/2024 at 18:44, 4 hours 44 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/19/2024 at 18:03, 5 hours 25 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 09/19/2024 at 17:52, 5 hours 36 minutes ago PILOT 28 : FIGEAC AÉRO remporte 3 nouveaux contrats sur l'A320 pour 65 millions d'euros
Published on 09/19/2024 at 17:52, 5 hours 36 minutes ago PILOT 28: FIGEAC AÉRO secures 3 new wins on the A320 airframe for 65 million euros
Published on 09/19/2024 at 17:45, 5 hours 43 minutes ago Gimv draagt helft van participatie in Infravest over aan WorxInvest (communicatie in toepassing van artikel 7:97 WVV)
Published on 09/19/2024 at 17:45, 5 hours 43 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)
Published on 09/19/2024 at 17:45, 5 hours 43 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)